Mean scores of the subgroups of the QUALEFFO before and 2 weeks after therapy in 18 patients treated by PV and 16 patients treated by OPM; absolute differences and 95% CI of the differences between patients after PV and patients treated by OPM
| QUALEFFO | PV (n = 18) | OPM (n = 16) | Difference PV–OPM | 95% CI Difference |
|---|---|---|---|---|
| Initial scores | ||||
| Pain | 19 | 21 | −2 | −3.6–0.4 |
| Function | 10 | 12 | −2 | −5.3–0.6 |
| Mobility | 18 | 20 | −2 | −5.9–1.4 |
| Stature | 23 | 27 | −4 | −9.6–1.5 |
| Social | 26 | 27 | −1 | −4.7–2.9 |
| Quality of life | 11 | 12 | −1 | −2.3–0.9 |
| Emotion | 31 | 33 | −2 | −4.0–0.6 |
| 2 Weeks after therapy | ||||
| Pain | 14 | 20 | −6 | −8.5–−2.5 |
| Function | 8 | 13 | −5 | −7.5–−2.0 |
| Mobility | 16 | 20 | −4 | −8.3–−0.3 |
| Stature | 21 | 27 | −6 | −11.8–−1.0 |
| Social | 25 | 26 | −1 | −4.6–3.5 |
| Quality of life | 11 | 12 | −1 | −2.9–0.3 |
| Emotion | 31 | 32 | −1 | −3.2–1.2 |
Note:—QUALEFFO, Quality of Life Questionnaire of the European Foundation for Osteoporosis; PV, percutaneous vertebroplasty; OPM, optimal pain medication; CI, confidence interval.